Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Pancreatic ductal adenocarcinoma (PDAC) exhibits a dismal prognosis driven by the interplay between dysregulated cell cycle progression in malignant cells and an immunosuppressive tumor microenvironment (TME). Proliferative PDAC subtypes are characterized by heightened immunosuppressive signatures and diminished cytotoxic CD8+ T cell infiltration.
Pancreatic ductal adenocarcinoma (PDAC) is a dismal malignancy with a 5-year survival rate of less than 8%, and its incidence has risen continuously in recent years [1x[1]Siegel, R.L., Miller, K.D., and Jemal, A. Cancer statistics, 2018. Ca - Cancer J Clin.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
